JP2021518748A5 - - Google Patents
Info
- Publication number
- JP2021518748A5 JP2021518748A5 JP2020544204A JP2020544204A JP2021518748A5 JP 2021518748 A5 JP2021518748 A5 JP 2021518748A5 JP 2020544204 A JP2020544204 A JP 2020544204A JP 2020544204 A JP2020544204 A JP 2020544204A JP 2021518748 A5 JP2021518748 A5 JP 2021518748A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- substantially similar
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634643P | 2018-02-23 | 2018-02-23 | |
| US62/634,643 | 2018-02-23 | ||
| PCT/US2019/019319 WO2019165326A1 (en) | 2018-02-23 | 2019-02-23 | Calcitonin gene-related peptide (cgrp) antagonist antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021518748A JP2021518748A (ja) | 2021-08-05 |
| JP2021518748A5 true JP2021518748A5 (enExample) | 2022-02-25 |
Family
ID=67688456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544204A Pending JP2021518748A (ja) | 2018-02-23 | 2019-02-23 | カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11629184B2 (enExample) |
| EP (1) | EP3755327A4 (enExample) |
| JP (1) | JP2021518748A (enExample) |
| CN (1) | CN112040949A (enExample) |
| WO (1) | WO2019165326A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117916259A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cgrp和pacap的抗原结合分子及其医药用途 |
| US20260125454A1 (en) * | 2022-08-11 | 2026-05-07 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cgrp antibody and use |
| CN117482233A (zh) * | 2023-11-01 | 2024-02-02 | 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) | Cgrp作为治疗靶点在筛选、开发治疗角膜损伤和神经再生药物中的应用 |
| CN118271438B (zh) * | 2024-05-27 | 2024-08-30 | 上海宏成药业有限公司 | 抗cgrp抗体或其抗原结合片段及其用途 |
| WO2026098547A1 (zh) * | 2024-11-08 | 2026-05-15 | 湖北生物医药产业技术研究院有限公司 | 一种靶向cgrp的抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
| US20080171038A1 (en) * | 2006-11-08 | 2008-07-17 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| KR20100115340A (ko) * | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| EP2516470B1 (en) * | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| CN105777907B (zh) * | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EP2906596B1 (en) * | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| US9629801B2 (en) * | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| WO2015199618A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| EP3200822B1 (en) * | 2014-09-30 | 2021-04-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Binding molecules, especially antibodies, binding to l1cam (cd171) |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
-
2019
- 2019-02-23 WO PCT/US2019/019319 patent/WO2019165326A1/en not_active Ceased
- 2019-02-23 US US16/975,120 patent/US11629184B2/en active Active
- 2019-02-23 EP EP19756784.5A patent/EP3755327A4/en not_active Withdrawn
- 2019-02-23 JP JP2020544204A patent/JP2021518748A/ja active Pending
- 2019-02-23 CN CN201980027708.7A patent/CN112040949A/zh active Pending